Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Frexalimab (Primary) ; Frexalimab (Primary)
Indications Multiple sclerosis
Focus Proof of concept; Therapeutic Use
Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

Most Recent Events

28 Jun 2024 According to a Sanofi media release, New phase 2 results were presented at the 10th Congress of the European Academy of Neurology (EAN) in Helsinki, Finland.
28 Jun 2024 New phase 2 results presented in a Sanofi Media Release.
18 Apr 2024 Results assessing Efficacy of Frexalimab,presented at the 76th Annual Meeting of the American Academy of Neurology 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com